CN104547709A - 一种用于治疗梅尼埃病的中药组合物及其制备方法和应用 - Google Patents
一种用于治疗梅尼埃病的中药组合物及其制备方法和应用 Download PDFInfo
- Publication number
- CN104547709A CN104547709A CN201510029522.9A CN201510029522A CN104547709A CN 104547709 A CN104547709 A CN 104547709A CN 201510029522 A CN201510029522 A CN 201510029522A CN 104547709 A CN104547709 A CN 104547709A
- Authority
- CN
- China
- Prior art keywords
- parts
- radix
- rhizoma
- meniere
- treatment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 23
- 238000002360 preparation method Methods 0.000 title claims abstract description 14
- 208000027530 Meniere disease Diseases 0.000 title abstract 3
- 239000003814 drug Substances 0.000 claims description 44
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 12
- 229940079593 drug Drugs 0.000 claims description 10
- 239000000843 powder Substances 0.000 claims description 8
- 238000000034 method Methods 0.000 claims description 7
- 235000019359 magnesium stearate Nutrition 0.000 claims description 6
- 210000000582 semen Anatomy 0.000 claims description 6
- 239000009636 Huang Qi Substances 0.000 claims description 5
- 241000244155 Taenia Species 0.000 claims description 5
- 230000003203 everyday effect Effects 0.000 claims description 3
- 239000000706 filtrate Substances 0.000 claims description 3
- 239000008187 granular material Substances 0.000 claims description 3
- 238000002156 mixing Methods 0.000 claims description 3
- 239000008194 pharmaceutical composition Substances 0.000 claims description 3
- 230000000694 effects Effects 0.000 abstract description 17
- 235000013399 edible fruits Nutrition 0.000 abstract description 3
- 241001061264 Astragalus Species 0.000 abstract description 2
- 240000002948 Ophiopogon intermedius Species 0.000 abstract description 2
- 240000004534 Scutellaria baicalensis Species 0.000 abstract description 2
- 235000017089 Scutellaria baicalensis Nutrition 0.000 abstract description 2
- 235000006533 astragalus Nutrition 0.000 abstract description 2
- 239000002994 raw material Substances 0.000 abstract description 2
- 241000405414 Rehmannia Species 0.000 abstract 2
- 241000427159 Achyranthes Species 0.000 abstract 1
- 241000049624 Alisma plantago-aquatica subsp. orientale Species 0.000 abstract 1
- 244000144730 Amygdalus persica Species 0.000 abstract 1
- 235000010110 Astragalus glycyphyllos Nutrition 0.000 abstract 1
- 235000017166 Bambusa arundinacea Nutrition 0.000 abstract 1
- 235000017491 Bambusa tulda Nutrition 0.000 abstract 1
- 244000025254 Cannabis sativa Species 0.000 abstract 1
- 241000196324 Embryophyta Species 0.000 abstract 1
- 241000305492 Gastrodia Species 0.000 abstract 1
- 244000082204 Phyllostachys viridis Species 0.000 abstract 1
- 235000015334 Phyllostachys viridis Nutrition 0.000 abstract 1
- 241001522129 Pinellia Species 0.000 abstract 1
- 244000179560 Prunella vulgaris Species 0.000 abstract 1
- 235000006040 Prunus persica var persica Nutrition 0.000 abstract 1
- 244000299790 Rheum rhabarbarum Species 0.000 abstract 1
- 235000009411 Rheum rhabarbarum Nutrition 0.000 abstract 1
- 240000006079 Schisandra chinensis Species 0.000 abstract 1
- 244000081822 Uncaria gambir Species 0.000 abstract 1
- 239000000853 adhesive Substances 0.000 abstract 1
- 230000001070 adhesive effect Effects 0.000 abstract 1
- 239000011425 bamboo Substances 0.000 abstract 1
- 235000005272 common selfheal Nutrition 0.000 abstract 1
- 229920001971 elastomer Polymers 0.000 abstract 1
- 229910052595 hematite Inorganic materials 0.000 abstract 1
- 239000011019 hematite Substances 0.000 abstract 1
- LIKBJVNGSGBSGK-UHFFFAOYSA-N iron(3+);oxygen(2-) Chemical compound [O-2].[O-2].[O-2].[Fe+3].[Fe+3] LIKBJVNGSGBSGK-UHFFFAOYSA-N 0.000 abstract 1
- SZVJSHCCFOBDDC-UHFFFAOYSA-N iron(II,III) oxide Inorganic materials O=[Fe]O[Fe]O[Fe]=O SZVJSHCCFOBDDC-UHFFFAOYSA-N 0.000 abstract 1
- 239000005060 rubber Substances 0.000 abstract 1
- 241000699670 Mus sp. Species 0.000 description 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 10
- 206010039897 Sedation Diseases 0.000 description 9
- 230000036280 sedation Effects 0.000 description 9
- 201000010099 disease Diseases 0.000 description 8
- 208000002173 dizziness Diseases 0.000 description 8
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- 206010047700 Vomiting Diseases 0.000 description 5
- 210000003169 central nervous system Anatomy 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 230000008673 vomiting Effects 0.000 description 4
- 206010009866 Cold sweat Diseases 0.000 description 3
- 206010011878 Deafness Diseases 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 241000283973 Oryctolagus cuniculus Species 0.000 description 3
- QGMRQYFBGABWDR-UHFFFAOYSA-M Pentobarbital sodium Chemical compound [Na+].CCCC(C)C1(CC)C(=O)NC(=O)[N-]C1=O QGMRQYFBGABWDR-UHFFFAOYSA-M 0.000 description 3
- 230000001773 anti-convulsant effect Effects 0.000 description 3
- 230000002567 autonomic effect Effects 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 230000036772 blood pressure Effects 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 229960002275 pentobarbital sodium Drugs 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- KWGRBVOPPLSCSI-WPRPVWTQSA-N (-)-ephedrine Chemical compound CN[C@@H](C)[C@H](O)C1=CC=CC=C1 KWGRBVOPPLSCSI-WPRPVWTQSA-N 0.000 description 2
- 206010001324 Adrenal atrophy Diseases 0.000 description 2
- MQVRGDZCYDEQML-UHFFFAOYSA-N Astragalin Natural products C1=CC(OC)=CC=C1C1=C(OC2C(C(O)C(O)C(CO)O2)O)C(=O)C2=C(O)C=C(O)C=C2O1 MQVRGDZCYDEQML-UHFFFAOYSA-N 0.000 description 2
- 206010010904 Convulsion Diseases 0.000 description 2
- OMFXVFTZEKFJBZ-UHFFFAOYSA-N Corticosterone Natural products O=C1CCC2(C)C3C(O)CC(C)(C(CC4)C(=O)CO)C4C3CCC2=C1 OMFXVFTZEKFJBZ-UHFFFAOYSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 208000031361 Hiccup Diseases 0.000 description 2
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical group NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 2
- 208000009205 Tinnitus Diseases 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 208000012886 Vertigo Diseases 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 229930013930 alkaloid Natural products 0.000 description 2
- 206010003549 asthenia Diseases 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 230000015271 coagulation Effects 0.000 description 2
- 238000005345 coagulation Methods 0.000 description 2
- 230000001143 conditioned effect Effects 0.000 description 2
- 230000036461 convulsion Effects 0.000 description 2
- OMFXVFTZEKFJBZ-HJTSIMOOSA-N corticosterone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@H](CC4)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OMFXVFTZEKFJBZ-HJTSIMOOSA-N 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 2
- 229960003957 dexamethasone Drugs 0.000 description 2
- 230000002124 endocrine Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 210000001508 eye Anatomy 0.000 description 2
- 238000012074 hearing test Methods 0.000 description 2
- 230000001077 hypotensive effect Effects 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 206010022437 insomnia Diseases 0.000 description 2
- 238000010253 intravenous injection Methods 0.000 description 2
- JPUKWEQWGBDDQB-QSOFNFLRSA-N kaempferol 3-O-beta-D-glucoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C(C=2C=CC(O)=CC=2)OC2=CC(O)=CC(O)=C2C1=O JPUKWEQWGBDDQB-QSOFNFLRSA-N 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 206010029864 nystagmus Diseases 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 230000001603 reducing effect Effects 0.000 description 2
- 230000011514 reflex Effects 0.000 description 2
- 230000035807 sensation Effects 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 231100000886 tinnitus Toxicity 0.000 description 2
- 230000001720 vestibular Effects 0.000 description 2
- DLNAGMLXUYEHQS-UHFFFAOYSA-N 3-O-beta-D-glucopyranosylserjanic acid Natural products COC(=O)C1(C)CCC2(CCC3(C)C(=CCC4C5(C)CCC(OC6OC(CO)C(O)C(O)C6O)C(C)(C)C5CCC34C)C2C1)C(=O)O DLNAGMLXUYEHQS-UHFFFAOYSA-N 0.000 description 1
- 235000005749 Anthriscus sylvestris Nutrition 0.000 description 1
- 244000221226 Armillaria mellea Species 0.000 description 1
- 235000011569 Armillaria mellea Nutrition 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 206010053567 Coagulopathies Diseases 0.000 description 1
- 206010051625 Conjunctival hyperaemia Diseases 0.000 description 1
- 206010010741 Conjunctivitis Diseases 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- 206010012218 Delirium Diseases 0.000 description 1
- 206010012374 Depressed mood Diseases 0.000 description 1
- 241000208011 Digitalis Species 0.000 description 1
- 206010013786 Dry skin Diseases 0.000 description 1
- 206010014020 Ear pain Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 208000032456 Hemorrhagic Shock Diseases 0.000 description 1
- 101000599862 Homo sapiens Intercellular adhesion molecule 3 Proteins 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 206010062717 Increased upper airway secretion Diseases 0.000 description 1
- 102100037871 Intercellular adhesion molecule 3 Human genes 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- 208000019695 Migraine disease Diseases 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 206010049771 Shock haemorrhagic Diseases 0.000 description 1
- 241001601725 Sthenias Species 0.000 description 1
- 206010042674 Swelling Diseases 0.000 description 1
- IUJDSEJGGMCXSG-UHFFFAOYSA-N Thiopental Chemical compound CCCC(C)C1(CC)C(=O)NC(=S)NC1=O IUJDSEJGGMCXSG-UHFFFAOYSA-N 0.000 description 1
- 206010044565 Tremor Diseases 0.000 description 1
- 208000003443 Unconsciousness Diseases 0.000 description 1
- 229930003448 Vitamin K Natural products 0.000 description 1
- 208000031975 Yang Deficiency Diseases 0.000 description 1
- 201000004484 acute conjunctivitis Diseases 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- IAJILQKETJEXLJ-QTBDOELSSA-N aldehydo-D-glucuronic acid Chemical compound O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C(O)=O IAJILQKETJEXLJ-QTBDOELSSA-N 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 150000003797 alkaloid derivatives Chemical class 0.000 description 1
- 229960005143 amobarbital sodium Drugs 0.000 description 1
- 230000003444 anaesthetic effect Effects 0.000 description 1
- 230000036592 analgesia Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000001754 anti-pyretic effect Effects 0.000 description 1
- 239000002221 antipyretic Substances 0.000 description 1
- VMWNQDUVQKEIOC-CYBMUJFWSA-N apomorphine Chemical compound C([C@H]1N(C)CC2)C3=CC=C(O)C(O)=C3C3=C1C2=CC=C3 VMWNQDUVQKEIOC-CYBMUJFWSA-N 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 210000005252 bulbus oculi Anatomy 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 235000013877 carbamide Nutrition 0.000 description 1
- 230000003727 cerebral blood flow Effects 0.000 description 1
- 210000003710 cerebral cortex Anatomy 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 229940126678 chinese medicines Drugs 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 230000035602 clotting Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 229910000365 copper sulfate Inorganic materials 0.000 description 1
- ARUVKPQLZAKDPS-UHFFFAOYSA-L copper(II) sulfate Chemical compound [Cu+2].[O-][S+2]([O-])([O-])[O-] ARUVKPQLZAKDPS-UHFFFAOYSA-L 0.000 description 1
- KWGRBVOPPLSCSI-UHFFFAOYSA-N d-ephedrine Natural products CNC(C)C(O)C1=CC=CC=C1 KWGRBVOPPLSCSI-UHFFFAOYSA-N 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000035619 diuresis Effects 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 208000007176 earache Diseases 0.000 description 1
- 210000003060 endolymph Anatomy 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000001667 episodic effect Effects 0.000 description 1
- 238000002481 ethanol extraction Methods 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 239000003172 expectorant agent Substances 0.000 description 1
- 230000003419 expectorant effect Effects 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 238000002523 gelfiltration Methods 0.000 description 1
- 229940097043 glucuronic acid Drugs 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 208000023513 hiccough Diseases 0.000 description 1
- 208000021760 high fever Diseases 0.000 description 1
- 229960001340 histamine Drugs 0.000 description 1
- 230000000147 hypnotic effect Effects 0.000 description 1
- 210000003026 hypopharynx Anatomy 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000002386 leaching Methods 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 239000012567 medical material Substances 0.000 description 1
- 206010027175 memory impairment Diseases 0.000 description 1
- 239000000401 methanolic extract Substances 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 206010027599 migraine Diseases 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 230000036407 pain Effects 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 208000026435 phlegm Diseases 0.000 description 1
- SHUZOJHMOBOZST-UHFFFAOYSA-N phylloquinone Natural products CC(C)CCCCC(C)CCC(C)CCCC(=CCC1=C(C)C(=O)c2ccccc2C1=O)C SHUZOJHMOBOZST-UHFFFAOYSA-N 0.000 description 1
- -1 phytosterol Natural products 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 208000037920 primary disease Diseases 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 1
- 208000012802 recumbency Diseases 0.000 description 1
- 230000002787 reinforcement Effects 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- 230000004799 sedative–hypnotic effect Effects 0.000 description 1
- 239000000344 soap Substances 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- BNHGKKNINBGEQL-UHFFFAOYSA-M sodium;5-ethyl-5-(3-methylbutyl)pyrimidin-3-ide-2,4,6-trione Chemical compound [Na+].CC(C)CCC1(CC)C(=O)NC(=O)[N-]C1=O BNHGKKNINBGEQL-UHFFFAOYSA-M 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 230000008925 spontaneous activity Effects 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 210000004233 talus Anatomy 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 231100000889 vertigo Toxicity 0.000 description 1
- 235000019168 vitamin K Nutrition 0.000 description 1
- 239000011712 vitamin K Substances 0.000 description 1
- 150000003721 vitamin K derivatives Chemical class 0.000 description 1
- 229940046010 vitamin k Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/233—Bupleurum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/26—Iron; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/21—Amaranthaceae (Amaranth family), e.g. pigweed, rockwort or globe amaranth
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/481—Astragalus (milkvetch)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/536—Prunella or Brunella (selfheal)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/539—Scutellaria (skullcap)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/57—Magnoliaceae (Magnolia family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/70—Polygonaceae (Buckwheat family), e.g. spineflower or dock
- A61K36/708—Rheum (rhubarb)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
- A61K36/736—Prunus, e.g. plum, cherry, peach, apricot or almond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/74—Rubiaceae (Madder family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/79—Schisandraceae (Schisandra family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/80—Scrophulariaceae (Figwort family)
- A61K36/804—Rehmannia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/884—Alismataceae (Water-plantain family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/888—Araceae (Arum family), e.g. caladium, calla lily or skunk cabbage
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/888—Araceae (Arum family), e.g. caladium, calla lily or skunk cabbage
- A61K36/8888—Pinellia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
- A61K36/8968—Ophiopogon (Lilyturf)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/898—Orchidaceae (Orchid family)
- A61K36/8988—Gastrodia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/899—Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation or decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Mycology (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Inorganic Chemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Neurosurgery (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
本发明公开了一种用于治疗梅尼埃病的中药组合物,是由按照重量份计的以下原料药制备得到的:柴胡7份,黄芩7份,法半夏6份,泽泻6份,桃仁6份,钩藤5份,代赭石5份,磁石5份,黄芪4份,竹茹4份,夏枯草4份,麦冬4份,牛膝4份,生地4份,五味子4份,石菖蒲4份,大黄4份,熟地4份,天麻4份;并提供了其制备方法和应用。本发明的有益效果为:本发明提供的一种用于治疗梅尼埃病的中药组合物及其制备方法和应用,经379例病例证明,效果明显,治愈速度快,复发率低,市场前景良好。
Description
技术领域
本发明涉及中药领域,具体涉及一种用于治疗梅尼埃病的中药组合物及其制备方法和应用。
背景技术
梅尼埃病是因内淋巴病变所致的发作性眩晕,典型特征为突然发作的旋转性眩晕,感觉全身在旋转,或感觉周围物体在旋转,身体的一侧倾倒感,眼球震颤,有时伴有耳鸣,耳聋或有恶心、呕吐,出冷汗,属中医眩晕范畴。现代医学称耳眩晕。中医对本病古代就有明确的认识,与风疾扰耳,痰热扰耳,寒冰泛耳、肝火熏耳、肝阳扰耳,髓海不足,阳虚耳窍失聪,上气不足,肝脾两虚等有关,其急性发作属实或虚实夹杂,缓解期多属虚。该病多为常见病,治疗多无良方。
发明内容
本发明的目的就是针对上述现有技术中的缺陷,提供了一种有效的,可用于治疗梅尼埃病的中药组合物。
为了实现上述目的,本发明提供的技术方案为:一种用于治疗梅尼埃病的中药组合物,是由按照重量份计的以下原料药制备得到的:柴胡7份,黄芩7份,法半夏6份,泽泻6份,桃仁6份,钩藤5份,代赭石5份,磁石5份,黄芪4份,竹茹4份,夏枯草4份,麦冬4份,牛膝4份,生地4份,五味子4份,石菖蒲4份,大黄4份,熟地4份,天麻4份。
本发明的第二个目的是提供了上述的一种用于治疗梅尼埃病的中药组合物的制备方法,是按照配方量称取各原料药,取泽泻和天麻加工成细粉并过100目筛,得到泽泻-天麻粉,其余原料药煎煮3次后合并滤液浓缩成膏状,再加入泽泻-天麻粉,混匀后即可得到所述中药组合物。
本发明的第三个目的是提供了上述一种用于治疗梅尼埃病的中药组合物在制备治疗梅尼埃病的药物中的应用。
进一步的,上述的应用,将中药组合物过16目筛,制成颗粒并干燥,干燥温度为60℃以下,加入适量硬脂酸镁混合均匀,压片即可得到治疗梅尼埃病的药物;硬脂酸镁的加入量为药物组合物总质量的0.1%-1%。
进一步的,上述的应用,所述药物的使用方法为,每片药物含生药4.5g,口服,每次6片,每日3次,7天为一疗程。
所用原料药的作用:
柴胡:
柴胡对中枢神经系统的作用,有明显的镇静,镇痛,解热,降温等作用。许多实验证明,多种柴胡的制剂,以及柴胡的根,果实中提取的柴胡粗皂甙及柴胡皂贰元A等均有明显镇静作用,小鼠口服柴胡粗皂甙200-800mg/kg,即可出现镇静作用。小鼠攀登实验中,粗柴胡皂甙,有与眼尔通相似的明显镇静作用。口服液的半数抑制剂量(CD50) 347mg/kg粗皂甙对大鼠的条件性回避,逃避反应均有明显的抑制、有安定作用。
黄芩:
临床和动物实验证明,黄芩有镇静作用,其镇静作用可能与加强皮质抑制过程有关。黄芪甙能抑制小鼠的自发运动,作用强度与剂量有关。黄芩煎剂可使小鼠阳性条件反射的形成减慢,建立条件反射所需强化次数增加,这种镇静作用可能是高血压患者服用黄芩制剂后,自觉症状显著好转的原因之一。
半夏:
半夏加热炮制或加明矾、姜汁炮制的各种制剂,对去水吗啡、洋地黄、硫酸铜引起的呕吐,都有一定的镇吐作用,对呕吐中枢有抑制作用,其镇吐的有效成分是生物碱,植物固醇,甲硫氨酸,甘氨酸,葡萄糖醛酸或L-麻黄碱。
泽泻:
泽泻浸膏给犬和兔静脉注射,有降压作用,并持续半小时左右。煎剂和浸膏对人和多种动物有利尿作用,并使尿中钠、氯,钾和尿素的排泄量增加。
桃仁:
50%的桃仁提取液静脉注射可立即增加麻醉家兔脑血流量,降低脑血管阻力,使小鼠凝血时间延长,桃仁水煎剂具有兼容促进作用,但其所含的维生素K参与体内凝血酶元的合成以供正常凝血需要。
钩藤:
钩藤各种制剂,包括有钩藤的复方,单味钩藤煎剂,乙醇提取物,总生物碱、钩藤碱对各种动物的高血压都具有降压作用。另对于偏头痛、眩晕等都有很好的作用。
代赭石:
本品对中枢神经系统有明显的镇静作用。对麻醉兔的血压影响不大。
磁石:
有镇静作用、磁石可抑制中枢神经系统,有明显的镇静抗惊厥作用,炮制后的磁石与异戊巴比妥钠有协同作用,能延长对小鼠的睡眠时间。另有抗惊厥和补血作用。
黄芪:
对中枢神经系统的作用:给小鼠皮下注射黄芪可维持数小时的镇静作用,不影响戊巴比妥钠的睡眠时间,但能显著增加小鼠的自发活动。黄芪皂甙甲和棉毛黄芪甙50mg/kg,静脉注射可延长硫喷妥钠所致小鼠的睡眠时间。
竹茹:
竹茹与华夏两药均有化痰止呕之效,对胆虚疾热郁结而致的烦闷不宁、头晕目眩,呕吐哕逆之症,常相互为用。
夏枯草:
夏枯草煎剂,水浸出液,乙醇水浸出液,乙醇浸出液均可明显降低实验动物血压。中国产夏枯草甲醇提取物经凝胶过滤所得的水溶性成分具有组织胺样作用。
麦冬:
心烦失眠,惊悸健忘,肃上焦火,安神定悸,抗体克作用,麦冬注射液静注1g/100g能使失血性休克大鼠血压迅速回升。
牛膝:
牛膝能导致火热下行,己将上炎之火,降火热上炎,肝阳上亢,肝风内动,引火下行。
生地:
对内分泌的影响,动物实验证明,能对抗连续服用地塞米松后血浆皮质铜浓度的下降,并能防止肾上腺皮质萎缩。
五味子:
五味子能延续小鼠条件反射的形成,提高大脑皮质工作的能力,反感要器的感受能力,还能改善人的智力活动,提高工作效率,能改善视力,扩大视野,改善听力,提高皮肤感受器的分辨能力,以及改善中枢分辨器功能的效果。
石菖蒲:
有镇静抗惊厥的作用,主要的药理作用表现为中枢镇静,抗惊厥作用,石菖蒲水煎剂1-10g/kg及去油水煎剂,10-3Og/kg腹腔注射使小鼠自主活动度明显降低,与阈下催眠剂量的戊巴比妥钠有显著的协同作用。
大黄:
具有很强的清热泻火,泻下通便功用,适用于高热神昏、谵语发狂、火热上炎所致的头痛、目赤、耳痛、咽喉肿痛、风火眼痛等。
熟地:
用于心肝血虚、眩晕心悸、失眠健忘、耳鸣耳聋等症。对内分泌的影响,动物实验证明熟地黄,能对抗连续服用地塞米松后血浆皮质酮浓度的下降,并能防止肾上腺皮质萎缩。
天麻:
适用于肝风内动,惊痫抽搐,眼目昏花,不论寒热虚实皆可配伍应用。对中枢神经系统的作用,是具有镇静安眠作用,天麻水剂能抑制小鼠自主活动,能延长戊巴比妥钠的睡眠时间,蜜环菌发酵液也有相似的作用。
本发明的有益效果为:本发明提供的一种用于治疗梅尼埃病的中药组合物及其制备方法和应用,经379例病例证明,效果明显,治愈速度快,复发率低,市场前景良好。
具体实施方式
实施例1:
一、临床资料:
1、梅尼埃病诊断依据:
①典型发作史;
②参考听力检查及前庭功能检查;
③排除其他原因引起的眩晕疾病。
2、病例选择:
379病例中,男性178例,女性201例。
其中,汉族,男,78例,女76例;维吾尔族,男49例,女69例,回族,男31例,女35例,哈萨克族,男15例,女18例;蒙古族男5例,女3例。
治疗梅尼埃病379例中,经治疗1-4个疗程,痊愈345例,显效31例,好转8例,总有效率100%。
二、治疗方法:
1、本发明提供的中药组合物基本配方:
柴胡7kg,黄芩7kg,法半夏6kg,泽泻6kg,桃仁6kg,钩藤5kg,代赭石5kg,磁石5kg,黄芪4kg,竹茹4kg,夏枯草4kg,麦冬4kg,牛膝4kg,生地4kg,五味子4kg,石菖蒲4kg,大黄4kg,熟地4kg,天麻4kg,制成20000片。
2、制法:
准确称取加工过的药材,足量,把泽泻、天麻加工成细粉,过100目备用。其余诸药放煎药罐煎煮3次,合并3次滤液浓缩成膏状,加入上留存备药粉,混匀,过16目筛,制成颗粒,于60℃以下干燥,加入适量硬脂酸镁,混合均匀,压片即得;硬脂酸镁的加入量为药物组合物总质量的0.1%-1%。
3、用途:
梅尼埃病,其他原因引起的眩晕疾病。
4、用量:
口服,每次6片,每日3次,7天为1疗程,服药期间忌生冷,勿劳累,受凉。
5、规格:
每片含生药4.5g。
三、典型病例:
例1,赵某某,男,35岁,汉族,已婚,干部2004年3月18日,由家人陪同前来就诊,主诉正在办公室上班,突然感觉头晕,觉得自身也在旋转,恶心,想吐,身出冷汗,心慌、全身无力,觉着耳鸣,坐着重,躺着转。经查发现眼球震颤,即作实验室及辅助检查,耳邵检查,听力检查,前庭动能检查,甘油试验阳性,均符合梅尼埃病。
给服本发明药物予以治疗,口服,每次6片,日服3次,服2天后诸症减转,效不更方,继续服药7天。痊愈出院,随访8年未复发。
例2:马合布拉提,女,37岁维吾尔族,农民,2008年5月正在田里干活,突然感到头晕、恶心、呕吐、全身出冷汗,无力,觉着自身及周围都在转,心发慌,懒言,乏力,遂由家人陪同前来就诊。经检查双眼球震颤,经实验室及辅助检查,耳部检查,听力功能检查,前庭功能检查,甘油试验阳性,均符合梅尼埃病。
给服本发明药物,口服,每次6片,1天3次,服药3天后症状减轻,服5日后,诸症消失,1周后出院,随访5年未复发。
最后应说明的是:以上所述仅为本发明的优选实施例而已,并不用于限制本发明,尽管参照前述实施例对本发明进行了详细的说明,对于本领域的技术人员来说,其依然可以对前述各实施例所记载的技术方案进行修改,或者对其中部分技术特征进行等同替换。凡在本发明的精神和原则之内,所作的任何修改、等同替换、改进等,均应包含在本发明的保护范围之内。
Claims (5)
1.一种用于治疗梅尼埃病的中药组合物,其特征在于,是由按照重量份计的以下原料药制备得到的:柴胡7份,黄芩7份,法半夏6份,泽泻6份,桃仁6份,钩藤5份,代赭石5份,磁石5份,黄芪4份,竹茹4份,夏枯草4份,麦冬4份,牛膝4份,生地4份,五味子4份,石菖蒲4份,大黄4份,熟地4份,天麻4份。
2.根据权利要求1所述的一种用于治疗梅尼埃病的中药组合物的制备方法,其特征在于,是按照配方量称取各原料药,取泽泻和天麻加工成细粉并过100目筛,得到泽泻-天麻粉,其余原料药煎煮3次后合并滤液浓缩成膏状,再加入泽泻-天麻粉,混匀后即可得到所述中药组合物。
3.根据权利要求1或2所述的一种用于治疗梅尼埃病的中药组合物在制备治疗梅尼埃病的药物中的应用。
4.根据权利要求3所述的应用,其特征在于,将中药组合物过16目筛,制成颗粒并干燥,干燥温度为60℃以下,加入适量硬脂酸镁混合均匀,压片即可得到治疗梅尼埃病的药物;硬脂酸镁的加入量为药物组合物总质量的0.1%-1%。
5.根据权利要求4所述的应用,其特征在于,所述药物的使用方法为,每片药物含生药4.5g,口服,每次6片,每日3次,7天为一疗程。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201510029522.9A CN104547709B (zh) | 2015-01-21 | 2015-01-21 | 一种用于治疗梅尼埃病的中药组合物及其制备方法和应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201510029522.9A CN104547709B (zh) | 2015-01-21 | 2015-01-21 | 一种用于治疗梅尼埃病的中药组合物及其制备方法和应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN104547709A true CN104547709A (zh) | 2015-04-29 |
CN104547709B CN104547709B (zh) | 2017-12-19 |
Family
ID=53065480
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201510029522.9A Expired - Fee Related CN104547709B (zh) | 2015-01-21 | 2015-01-21 | 一种用于治疗梅尼埃病的中药组合物及其制备方法和应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN104547709B (zh) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105727045A (zh) * | 2016-04-15 | 2016-07-06 | 宁波优美科新材料有限公司 | 一种用于治疗梅尼埃病的药物 |
CN105999206A (zh) * | 2016-08-13 | 2016-10-12 | 华梅 | 一种治疗梅尼埃病的中药组合物及其制备方法 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102861242A (zh) * | 2011-07-05 | 2013-01-09 | 徐浩 | 一种预防和治疗眩晕的中药组合物及其制备方法 |
CN104013847A (zh) * | 2014-06-16 | 2014-09-03 | 孙喜范 | 一种治疗梅尼埃病中药 |
CN104173834A (zh) * | 2014-09-02 | 2014-12-03 | 马振兰 | 一种治疗梅尼埃病的中药 |
-
2015
- 2015-01-21 CN CN201510029522.9A patent/CN104547709B/zh not_active Expired - Fee Related
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102861242A (zh) * | 2011-07-05 | 2013-01-09 | 徐浩 | 一种预防和治疗眩晕的中药组合物及其制备方法 |
CN104013847A (zh) * | 2014-06-16 | 2014-09-03 | 孙喜范 | 一种治疗梅尼埃病中药 |
CN104173834A (zh) * | 2014-09-02 | 2014-12-03 | 马振兰 | 一种治疗梅尼埃病的中药 |
Non-Patent Citations (1)
Title |
---|
张桂英等: "清肝镇眩汤治疗梅尼埃病96例", 《河北中医》 * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105727045A (zh) * | 2016-04-15 | 2016-07-06 | 宁波优美科新材料有限公司 | 一种用于治疗梅尼埃病的药物 |
CN105999206A (zh) * | 2016-08-13 | 2016-10-12 | 华梅 | 一种治疗梅尼埃病的中药组合物及其制备方法 |
Also Published As
Publication number | Publication date |
---|---|
CN104547709B (zh) | 2017-12-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN102198236B (zh) | 一种治疗急性鼻窦炎的中药组合物及其制备方法 | |
CN102302563B (zh) | 一种治疗慢性肾功能衰竭的中药组合物及其制备方法 | |
CN105998237B (zh) | 一种治疗抑郁性失眠症的中药组合物 | |
CN105902906A (zh) | 一种治疗风寒感冒咳嗽的中药组合物及其制备方法 | |
CN103223118B (zh) | 一种治疗面瘫的中药组合物 | |
CN102526677A (zh) | 治疗风寒感冒的中药足浴组合物 | |
CN102085299B (zh) | 治疗前列腺炎的中成药物及其制备方法 | |
CN106334107A (zh) | 一种中药眼药水及其制备方法 | |
CN104398980A (zh) | 一种治疗中风后偏瘫的中药制剂及其制备方法 | |
CN102302733B (zh) | 治疗卵巢囊肿的内服中药组合物 | |
CN103830588A (zh) | 一种治疗儿童多动症的中药制剂 | |
CN104547709A (zh) | 一种用于治疗梅尼埃病的中药组合物及其制备方法和应用 | |
CN101496889A (zh) | 一种用于定志安神、舒肝解郁的中药组合及其制备方法 | |
CN105456818A (zh) | 一种含有艾叶的治疗失眠的中药组合物及其制备方法 | |
CN105497789A (zh) | 一种治疗脑卒中后抑郁症的中药制剂及其制备方法 | |
CN104257763A (zh) | 一种肉苁蓉水提取物、制备方法及其用途 | |
CN105381289A (zh) | 一种治疗月经不调的药物组合物 | |
CN105343675A (zh) | 一种治疗肥胖症的中药制剂及其制备方法 | |
CN104324274A (zh) | 一种治疗甲状腺功能亢进症的中药及其制备方法 | |
CN104524479A (zh) | 一种治疗经前期综合征的中药组合物及其制备方法 | |
CN103494939A (zh) | 一种治疗老年习惯性便秘的中药 | |
CN102698073A (zh) | 一种治疗过敏性鼻炎的中药浸膏 | |
CN103520354A (zh) | 一种治疗血虚型乳腺增生的中药及制备方法 | |
CN103301429B (zh) | 治疗妇女痛经的口服制剂 | |
CN102552423B (zh) | 一种治疗偏头痛的药物组合物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20171219 Termination date: 20200121 |
|
CF01 | Termination of patent right due to non-payment of annual fee |